Recursion Pharmaceuticals (RXRX) Debt to Equity (2020 - 2025)
Historic Debt to Equity for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $0.02.
- Recursion Pharmaceuticals' Debt to Equity fell 6368.8% to $0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.02, marking a year-over-year decrease of 6368.8%. This contributed to the annual value of $0.03 for FY2024, which is 97639.01% up from last year.
- Latest data reveals that Recursion Pharmaceuticals reported Debt to Equity of $0.02 as of Q3 2025, which was down 6368.8% from $0.02 recorded in Q2 2025.
- In the past 5 years, Recursion Pharmaceuticals' Debt to Equity ranged from a high of $0.05 in Q3 2024 and a low of -$0.04 during Q1 2021
- In the last 5 years, Recursion Pharmaceuticals' Debt to Equity had a median value of $0.0 in 2023 and averaged $0.01.
- As far as peak fluctuations go, Recursion Pharmaceuticals' Debt to Equity plummeted by 9086.58% in 2022, and later skyrocketed by 205571.7% in 2024.
- Recursion Pharmaceuticals' Debt to Equity (Quarter) stood at $0.0 in 2021, then dropped by 5.37% to $0.0 in 2022, then surged by 123.34% to $0.0 in 2023, then skyrocketed by 976.39% to $0.03 in 2024, then fell by 25.02% to $0.02 in 2025.
- Its Debt to Equity was $0.02 in Q3 2025, compared to $0.02 in Q2 2025 and $0.03 in Q1 2025.